{"id":"W4409144909","doi":"10.1016/j.ejcskn.2025.100586","title":"A Phase 3 trial of fixed-dose combination of fianlimab + cemiplimab vs relatlimab + nivolumab in patients with unresectable or metastatic melanoma","year":2025,"lang":"en","type":"article","venue":"EJC Skin Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Nivolumab; Medicine; Oncology; Melanoma; Internal medicine; Phase (matter); Metastatic melanoma; Radiology; Cancer research; Immunotherapy; Cancer; Physics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003025692,0.0001893789,0.0006368303,0.0003538756,0.00003739374,0.00000993798,0.0001352678,0.00008450796,0.0005231688],"category_scores_gemma":[0.00009946607,0.0001411539,0.000112027,0.001004623,0.0001303116,0.0001207782,0.00003358244,0.0001681172,0.000001282152],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003916392,"about_ca_system_score_gemma":0.0007615844,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001275998,"about_ca_topic_score_gemma":0.0005614326,"domain_scores_codex":[0.9983095,0.00008806966,0.0006250029,0.0002857719,0.0004394057,0.0002522364],"domain_scores_gemma":[0.9989191,0.0001572917,0.0003117111,0.0003608894,0.0002102383,0.000040798],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.914375,0.008241073,0.02592525,0.0006999059,0.0007816792,0.00001634963,0.0007866034,0.00001622686,0.001109774,0.00007950501,0.002396537,0.04557211],"study_design_scores_gemma":[0.8661351,0.01687494,0.09389292,0.00192767,0.0004985715,0.000002258391,0.0002472341,0.0002757132,0.01571011,0.00008042104,0.004082482,0.0002725315],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9953731,0.0009019573,0.00005052413,0.0004029711,0.0003450094,0.00156402,0.0001121348,0.00001673418,0.001233557],"genre_scores_gemma":[0.9976116,0.0001720433,0.0002737061,0.0001550165,0.00002253813,0.0001819974,0.00007129837,0.00002364561,0.001488107],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.06796767,"threshold_uncertainty_score":0.575609,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01461065501911946,"score_gpt":0.3161808704942925,"score_spread":0.301570215475173,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}